Abstract: The invention concerns an endovascular implant comprising a biodegradable material and having a tubular main body which is open at the ends and which is dilatable from an unexpanded condition into an expanded condition. The implant is so designed that when the implant in the expanded condition is subjected to a radially acting compression pressure in the range of between 5 and 30 kPa (0.05-0.3 bar) a cross-sectional area of the implant is reduced to 70% or less of the original cross-sectional area, or an internal volume of the implant is reduced to 70% or less of the original internal volume.

Abstract: An implant for releasing an active substance into a vessel through which a body medium flows. The implant release an active substance into a vessel through which a body medium flows downstream from the location of the implant. A base of a biodegradable material is a carrier of the active substance to be released. The body medium flows past the implant and the active substance is release. The implant is configured so that the active substance does not contact a vessel wall at the location of implant.

Abstract: A radio-opaque marker for medical implants comprising between 10 and 90 weight percent of a biodegradable base component, between 10 and 90 weight percent of one or more radio-opaque elements selected from the consisting of I, Au, Ta, Y, Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir and Bi as a marker component and 10 weight percent of residual components, the aforementioned components amounting to 100 weight percent.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: The aim of the invention is to provide an implant for releasing an active substance into a vessel through which a body medium flows. This aim is achieved by the inventive implant for releasing an active substance into a vessel through which a body medium flows. Said implant comprises a base that consists of a biodegradable material as the carrier of the active substance to be released. The body medium flows around said base on the inside and/or outside thereof.

Abstract: The invention relates to a radio-opaque marker for medical implants. Said marker contains between 10 and 90 weight percent of a biodegradable base component, between 10 and 90 weight percent of one or more radio-opaque elements from the group containing I, Au, Ta, Y, Nb, Mo, Ru, Rh, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir and Bi as a marker component and 10 weight percent oF residual components, the aforementioned components amounting to 100 weight percent.

Abstract: A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells.

Abstract: The invention concerns an endovascular implant comprising a biodegradable material and having a tubular main body which is open at the ends and which is dilatable from an unexpanded condition into an expanded condition. The implant is so designed that when the implant in the expanded condition is subjected to a radially acting compression pressure in the range of between 5 and 30 kPa (0.05-0.3 bar) a cross-sectional area of the implant is reduced to 70% or less of the original cross-sectional area, or an internal volume of the implant is reduced to 70% or less of the original internal volume.

Abstract: The invention concerns inter alia an implant for vessel ligature, the implant which comprises an alloy, wherein the alloy is at least partially biodegradable, and wherein the alloy comprises: greater than 87% magnesium; from about 3% to about 6% yttrium; from about 1% to about 5% lanthanide; and a balance of about 0.0% to about 2%.